Global CRO scale Fortrea is a global clinical development provider with a large, diverse workforce (about 19,000 employees) operating in over 90 countries, presenting significant opportunities to cross-sell integrated trial management, pharmacovigilance, and post-approval services to multinational biopharma and medical device clients.

Technology launched Recent introduction of Fortrea Intelligent Technology (FIT) signals a focus on technology-enabled trial solutions, offering a sales path to offer clients advanced data integration, trial management efficiency, and digital safety monitoring capabilities within existing service lines.

Therapy expansion Fortrea’s involvement across more than 20 therapeutic areas and new CGT collaborations (cell and gene therapy) indicates expansion into high-growth modalities, suggesting cross-sell opportunities with sponsors pursuing CGT development and integrated clinical and production services.

Leadership and strategy Recent leadership changes and board appointments, including new president of CPS and governance additions, point to strategic investments in early development, growth execution, and competitive positioning—opportunities to engage on roadmap alignment and enterprise partnerships.

Financial foothold With reported revenue in the tens of millions range and a broad global footprint, Fortrea demonstrates scale that can support larger, multi-year outsourcing deals, making it a viable partner for sponsors seeking end-to-end CRO and post-approval solutions.